What is your treatment of choice in ALK-positive lung adenocarcinomas that have progressed on alectinib with resistance mutations that are not G1202R?

Lorlatinib has high response rates with any resistance mechanism.

Data regarding use of lorlatinib after 1st or 2nd generation ALK-TKI failure comes from a phase II trial that enrolled multiple cohorts based on number/type of treatments received (i.e., 1st or 2nd gen. ALK-TKI with or without chemotherapy) (Shaw et al., PMID 30892989).

In this study, patients who ha...